Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × ALK-positive NSCLC × lorlatinib × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 8 Sexual Dysfunction, Physiological 1 Neuroblastoma 1 Neoplasm Metastasis 1 Meningeal Carcinomatosis 1 Lung Diseases 1 Hyperlipidemias 1 Eunuchism 1 Erectile Dysfunction 1 Brain Neoplasms 1 ALK-positive Non-small Cell Lung Cancer 1 ALK-positive NSCLC 1

Interventions

lorlatinib 1 ceritinib 1 brigatinib 1 alectinib 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Pfizer

549 enrolled 28 charts

ALK-positive NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡